Dyne Therapeutics, Inc.
About Dyne Therapeutics, Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$446.2M
- Total assets
- $1.2B
- Market cap
- $2.8B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $468.2M
- Operating income
- -$468.2M
- Income tax
- $0
- Net income
- -$446.2M
- EPS (basic)
- $-3.47
- EPS (diluted)
- $-3.47
Balance sheet
- Total assets
- $1.2B
- Current assets
- $1.1B
- Total liabilities
- $214.8M
- Current liabilities
- $50.6M
- Shareholders’ equity
- $972.1M
Cash flow
- Operating cash flow
- -$403.2M
- Investing cash flow
- -$28.8M
- Financing cash flow
- $890.3M
- Net cash flow
- $458.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.8B
- EPS (diluted)
- $-3.47
- Shares outstanding
- 167.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 17, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $446.2M.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Dyne Therapeutics, Inc..
Write a review
News about Dyne Therapeutics, Inc.
News & sentiment via Polygon.io
